Concord Biotech
Concord Biotech Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Concord Biotech Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Concord Biotech Ltd trades at a P/E of 54.77× and P/B of 7.04×.
Valuation
Profitability
Growth
Financial Health
Concord Biotech Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Concord Biotech Ltd, switchable between annual and quarterly views, consolidated or standalone.
Concord Biotech Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹14,196.42 Cr and reported EPS of ₹24.72.
| Period | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue from Operations | 1,017 | 1,200 | 1,055 |
| Other Income | 34 | 44 | 52 |
| Total Income | 1,051 | 1,245 | 1,107 |
| Cost of Goods Sold (COGS) | 229 | 306 | 246 |
| Gross Profit | 788 | 895 | 809 |
| +Operating Expenses | 356 | 388 | 442 |
| EBITDA | 432 | 506 | 367 |
| +Non-Operating Expenses | 56 | 55 | 71 |
| Profit Before Tax (PBT) | 409 | 496 | 342 |
| +Tax Expense | 104 | 123 | 85 |
| Profit After Tax (PAT) | 308 | 372 | 259 |
| Earnings Per Share (EPS) | 29.45 | 35.52 | 24.94 |
| Diluted Shares Outstanding (Nos.) | 10 | 10 | 10 |
| +Additional Disclosures | 874 | 1,059 | 1,064 |
| Sales Growth % | — | 18.01 | -12.10 |
| YoY Sales Growth % | — | 18.01 | -12.10 |
| Material Cost % | 18 | 22 | 24 |
| Employee Cost % | 12 | 12 | 17 |
| Other Cost % | 23 | 21 | 25 |
| OPM % | 42 | 42 | 35 |
| Tax % | 26 | 25 | 25 |
| Profit Growth % | — | 20.62 | -30.25 |
| Gross Margin % | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 |
| Additional Fields | 378 | 452 | 293 |
Concord Biotech segment analysis: revenue and profit mix.
Disclosed business segments at Concord Biotech with their share of revenue and profit, switchable between consolidated and standalone reporting.
Concord Biotech discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Concord Biotech Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Concord Biotech Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Concord Biotech Ltd's investment case rests on 7 positive markers and 8 flagged concerns drawn from the latest reported filings.
What you're getting.
Concord Biotech demonstrates strong capital efficiency with a robust Return on Equity (ROE) of 21.30% and an impressive Return on Capital Employed (ROCE) of 28.20%. These figures highlight the company's effective utilization of shareholder funds and overall operational profitability.
The company maintains an exceptionally high Operating Profit Margin (OPM) of 40.60%, indicating strong pricing power and highly efficient cost management. This robust margin contributes significantly to its overall profitability and financial stability.
Concord Biotech boasts a remarkably strong balance sheet with a debt-to-equity ratio of 0.00, signifying virtually no financial leverage. This low debt profile provides significant financial flexibility and reduces risk for investors.
Institutional confidence is evident with DII holdings consistently increasing from 8.12% in Sep 2023 to 9.55% in Sep 2025, alongside FII holdings at 8.03%. This indicates growing institutional interest and belief in the company's prospects.
The global pharmaceuticals industry is poised for sustained growth, driven by an aging population, rising healthcare expenditure, and increasing prevalence of chronic diseases, offering Concord Biotech significant market expansion opportunities.
What can break it.
The stock has experienced significant volatility, with its 52-week high at ₹2451.70 and low at ₹1345.00. This wide price range indicates potential instability, which could be a concern for investors seeking more predictable returns.
The company reported a notable decline in recent quarterly profit, with a -26.10% variation in PAT. This significant drop in short-term profitability warrants close monitoring to understand underlying causes and potential impacts on future earnings.
Concord Biotech's Price-to-Earnings (P/E) ratio stands at 42.70, which is higher than several industry peers. This elevated valuation suggests the stock might be trading at a premium, requiring careful consideration by potential investors.
The company experienced a decline in recent quarterly sales, with a -5.47% variation. This negative sales growth could indicate challenges in market demand or increased competition, requiring further investigation into its revenue drivers.
The pharmaceutical sector is highly competitive, with numerous established players and new entrants. Intense competition from peers like Sun Pharma and Cipla could exert pressure on Concord Biotech's market share and pricing power.
What would change my mind.
Trim if P/E re-rates above 71. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 9%. The operating engine is no longer compounding capital efficiently.
Concord Biotech Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Concord Biotech Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Concord Biotech Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Concord Biotech Ltd — derived from the live tape, not yesterday's close.
Concord Biotech Ltd last traded at ₹1,353.8 with an intraday range of ₹1,335.6–₹1,367.4 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1353.80| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1432.53 | +78.73 | +5.82% |
| R3 | 1400.73 | +46.93 | +3.47% |
| R2 | 1384.07 | +30.27 | +2.24% |
| R1 | 1368.93 | +15.13 | +1.12% |
| PIVOT | 1352.27 | -1.53 | -0.11% |
| CURRENT | 1353.80 | — | — |
| S1 | 1273.53 | -80.27 | -5.93% |
| S2 | 1305.33 | -48.47 | -3.58% |
| S3 | 1320.47 | -33.33 | -2.46% |
| S4 | 1337.13 | -16.67 | -1.23% |
CONCORDBIO is trading Above CPR, indicating Bullishness
CPR is Narrower, suggesting likely for trending moves
Day's range: 1338.1 ~ 1364.3
Trading Above opening range, showing Bullishness
Concord Biotech Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Concord Biotech Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Concord Biotech Ltd stood at 46.9% of traded volume, against a 20-day average of 39.3%.
Concord Biotech announcements: results, concalls, ratings, M&A.
Filings Concord Biotech sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Concord Biotech files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 103 documents below.
Updates
Concord Biotech Limited has informed the Exchange regarding Abbreviated New Drug Application (ANDA) Approval for Mycophenolate Mofetil for Oral…
Investor Presentation
Concord Biotech Limited has informed the Exchange about Investor Presentation
Copy of Newspaper Publication
Concord Biotech Limited has informed the Exchange about Copy of Newspaper Publication
Outcome of Board Meeting
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Analysts/Institutional Investor Meet/Con. Call Updates
Concord Biotech Limited has informed the Exchange about Schedule of meet
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Concord Biotech dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Concord Biotech has declared, sequenced by announce and record date.
Concord Biotech corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Concord Biotech Ltd: business, sector, key facts.
What Concord Biotech Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Concord Biotech Ltd operates in the Healthcare, listed as NSE: CONCORDBIO, BSE: 543960.
Concord Biotech Limited is an Indian biopharmaceutical company specializing in the research, development, manufacturing, and sale of pharmaceutical products both domestically and internationally. Their core competency lies in fermentation-based Active Pharmaceutical Ingredients (APIs), which are essential components in various medications.
The company's product portfolio is diverse and spans several therapeutic areas. In immunosuppressants, they offer a range of key APIs including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus. Their oncology segment features APIs such as temsirolimus, everolimus, romidepsin, and several others used in cancer treatments. Concord Biotech also manufactures APIs for antibacterial applications, including mupirocin, polymyxin B sulfate, and fidaxomicin, and for antifungal treatments, offering anidulafungin, caspofungi, and more.
Beyond their own branded APIs, Concord Biotech provides contract research and manufacturing services (CRAMS) focused on fermentation and semi-synthesis products. This business model allows them to leverage their expertise in fermentation processes to offer services to other pharmaceutical companies, contributing to their revenue streams and expanding their reach within the industry.
Established in 1984 and headquartered in Ahmedabad, India, Concord Biotech has a long history in the pharmaceutical sector. Their focus on fermentation-based APIs, combined with their CRAMS services, positions them as a significant player in the global biopharmaceutical market, catering to a wide range of therapeutic needs and client demands. The company's continued success relies on their ability to innovate, maintain high manufacturing standards, and effectively navigate the complexities of the global pharmaceutical landscape.
Questions investors ask about Concord Biotech Ltd (CONCORDBIO).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Concord Biotech Ltd (CONCORDBIO)?
The current share price of Concord Biotech Ltd (CONCORDBIO) is ₹1,353.8. Today, the stock has gained by ₹10.50 (0.78%), trading in a range of ₹1,335.6 to ₹1,367.4. The stock opened at ₹1,345.1 with a trading volume of 3,58,864 shares.
02Is Concord Biotech Ltd stock a good investment for long-term?
Concord Biotech Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹14,196.42 crores, P/E ratio of 54.77, ROE of 13.54%, and ROCE of 28.20%. The dividend yield stands at 0.56%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Concord Biotech Ltd stock?
The 52-week high price of Concord Biotech Ltd (CONCORDBIO) is ₹0, while the 52-week low is ₹0. Currently trading at ₹1,353.8, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Concord Biotech Ltd stock at the current price?
Whether to buy Concord Biotech Ltd stock at ₹1,353.8 depends on multiple factors. The stock is currently trading with a P/E ratio of 54.77 and P/B ratio of 7.04. Today's performance shows a gain of 0.78%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Concord Biotech Ltd and when is the next dividend?
Concord Biotech Ltd offers a dividend yield of 0.56%, which means for every ₹100 invested at the current price of ₹1,353.8, you can expect to receive approximately ₹0.56 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Concord Biotech Ltd?
Concord Biotech Ltd's key financial metrics include: P/E Ratio: 54.77, P/B Ratio: 7.04, ROE: 13.54%, ROCE: 28.20%, Dividend Yield: 0.56%, EPS: ₹24.72, Book Value: ₹192.19, and Debt-to-Equity: 0.12. The company's market cap stands at ₹14,196.42 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Concord Biotech Ltd stock performing today in the market?
Concord Biotech Ltd stock opened at ₹1,345.1 and is currently trading at ₹1,353.8, showing a gain of ₹10.50 (0.78%). The intraday high is ₹1,367.4 and low is ₹1,335.6. The trading volume stands at 3,58,864 shares, indicating moderate market participation today.
08What is the P/E ratio of Concord Biotech Ltd and what does it indicate?
Concord Biotech Ltd has a Price-to-Earnings (P/E) ratio of 54.77, which means investors are willing to pay ₹54.77 for every ₹1 of earnings. With an EPS of ₹24.72, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Concord Biotech Ltd (CONCORDBIO) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy